Usefulness of 1H MR spectroscopy in the evaluation of myocardial metabolism in patients with dilated idiopathic cardiomyopathy: Pilot study

Academic Radiology

Volumn 10, Issue 10, 2003, Pages 1187-1192

  Walecki, Jerzy ^a   Michalak, Małgorzata J ^b   Michalak, Ewa ^c   Bilinska, Zofia T ^c   Ruzyllo, Witold ^c  

^a Medical Center of Postgraduate Education   (Poland)

^b Central Clinical Hospital   (Poland)

^c INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Echocardiography; Idiopathic dilated cardiomyopathy; Magnetic resonance proton spectroscopy; Metabolism

Indexed keywords

CREATINE; CREATINE PHOSPHATE; LACTIC ACID; LIPID;

ADULT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE METABOLISM; HEART VENTRICLE SEPTUM; HUMAN; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYMPTOMATOLOGY; ARTICLE; CHEMISTRY; ECHOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY;

ADULT; CARDIOMYOPATHY, DILATED; CREATINE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; LACTIC ACID; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MYOCARDIUM; PHOSPHOCREATINE; VENTRICULAR FUNCTION, LEFT;

EID: 0142059304     PISSN: 10766332     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1076-6332(03)00104-1     Document Type: Conference Paper

References (23)

1. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96:2190-2196.
2. Bottomley PA. MR spectroscopy of the human heart: the status and challenges. Radiology 1994; 191:593-612.
3. Hardy CJ, Weiss RG, Bottomley PA, et al. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991; 122:795-801.
4. Zaleska T, Walecki J, Michalak JM, et al. Spektroskopia magnetycznego rezonansu w kardiologii. Med Sci Rev 2002; 1:20-24.
5. Kozerke S, Schar M, Boesiger P. Navigator based gating and volume tracking for cardiac 1 H spectroscopy. MAGMA 2002; 15:106.
6. Kreis R. 1HMR spectroscopy outside the brain. MAGMA 2002; 151:2.
7. Felblinger J, Jung B, Slotboom J, et al. Methods and reproducibility of cardiac/respiratory double-triggered 1H-MR spectroscopy of the human heart. Magn Reson Med 1999; 42:140-148.
8. Zaleska T, Walecki J. Kliniczne zastosowanie spektroskopii rezonansu magnetycznego w kardiologii. Rez Magn Med 1996; 4(1):82-85.
9. Lee CW, Lee JH, Lim TH, et al. Prognostic significance of cerebral metabolic abnormalities in patients with congestive heart failure. Circulation 2002; 103:2784-2787.
10. Ashwal S, Holshouser B, Hinshaw DB, et al. Proton magnetic resonance spectroscopy in the evaluation of children with congenital heart disease and acute central nervous system injury. J Thorac Cardiovasc Surg 1996; 112:403-14.
11. Reeves RC, Evanochko WT, Canby RC, et al. Demonstration of increased myocardial lipid with postischemic dysfunction ("myocardial stunning") by proton nuclear magnetic resonance spectroscopy. J Am Coll Cardiol 1989; 13:739-44.
12. Walecki J, Michalak JM, Grieb P, et al. Rezonans magnetyczny w kardiologii-wprowadzenie do metody i zastosowanie. Problemy Lekarskie 2002; 41:62-72.
13. Ugurbil K, Petein M, Maidan R, et al. High resolution proton NMR studies of perfused rat hearts. FFBS lett 1984; 167:73-78.
14. Grieb P. Biomedyczne zastosowanie spektroskopii rezonansu magnetycznego (MRS). Rez Magn Med 1997; 5:5-9.
15. Walecki J, Michalak JM, Michalak E, et al. Zastosowanie spektroskopii magnetycznego rezonansu w kardiologii. State of the Art. Przeglad Lekarski 2002; 59; 8:601-605.
16. Toyo-oka T, Nagayama K, Suzuki J, et al. Noninvasive assessment of cardiomyopathy development with simultaneous measurement of topical 1H- and 31P-magnetic resonance spectroscopy. Circulation 1992; 86:295-301.
17. Evanochko WT. NMR spectroscopic assessment of altered myocardial lipid metabolism. Invest Radiol 1989; 24:973-975.
18. Evanochko WT, Reeves RC, Canby RC, et al. Proton MNR spectroscopic studies of stunned myocardium. Ann NY Acad Sci 1987; 508: 460-462.
19. Richards TL, Terrier F, Sievers E. Lactate accumulation in ischemic- and anoxic-isolated rat hearts assessed by H-1 spectroscopy. Invest Radiol 1987; 22:638-641.
20. Bilinska ZT, Ruzyllo W. Kardiomiopatia rozstrzeniowa rodzinna. In Ciechanowicz A, Januszewicz A, Januszewicz W, Ruzyllo W: Genetyka chorób ukladu krazenia. Medycyna Praktyczna, Kraków 2002; 105-110.
21. Bilinska ZT, Michalak E, Kuœmierczyk-Droszcz B, et al. Dilated cardiomyopathy-an ongoing prospective family study on 300 relatives. Circulation 1999; 100:I,382-A:2005.
22. Stanley WC, Berêsewicz A, Chandler MP. Metabolizm substratów energetycznych w normalnym i niewydolnym sercu i mozliwosci jego terapeutycznych modyfikacji. Kardiol Pol 2000; 53:111-54.
23. Paolisso G, Gambardella A, Galzerano D, et al. Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43:174-79.